Isoliquiritigenin ameliorates metabolic dysfunction-associated steatotic liver disease by modulating S100A8-associated MAPK signaling and ferroptosis-related processes
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) currently lacks effective targeted therapeutic approaches. Although isoliquiritigenin (ISL) exhibits hepatoprotective effects, its precise molecular target remains unclear. This study aims to identify the potential molecular target and mechani...